Back to search results

A Study of ABBV-547 in Healthy Volunteers

This study is looking for healthy volunteers, aged 18 to 55, to help understand how a new drug called ABBV-547 moves through the body, its side effects (adverse events), and how well people tolerate it. You would receive either ABBV-547 or a placebo (an inactive substance) through an injection. The main goal is to track any side effects for up to about 365 days. We are looking for about 121 participants across sites in the United States and Japan. You must be in good general health and have a Body Mass Index (BMI) between 18.0 and 29.9.

Study design
This is an interventional study with approximately 121 participants. You will be placed into one of several groups to receive different doses of ABBV-547 or a placebo.
What's involved
You will receive one injection of ABBV-547 or placebo. Your health will be monitored for up to approximately 365 days.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to approximately 365 days to monitor for adverse events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07232004

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

Active, Not Recruiting
PHASE1Ages 18–55InterventionalTreatment
AbbVie
~121 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:ABBV-547ABBV-547 Placebo

At a glance

Recruiting sites
0 of 23 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs)
Measured over Up to Approximately Day 365

Conditions

Healthy Volunteer

Explore related trials

Healthy Volunteer

Where it's being run

23 sites across 15 states
Florida4
California3
Illinois2
New York2
Texas2
Alabama1
Arkansas1
Massachusetts1

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).
Part 1: BMI is \>= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
Part 2: must have discontinued use of phototherapy (e.g., UVA or UVB) at least 2 weeks prior to the baseline visit (Day 1) and PUVA phototherapy at least 4 weeks prior to the baseline visit (Day 1).

Exclusion

History of any clinically significant sensitivity or allergy to any medication or food.
Part 2: uses any herbal supplements within the 2-week period prior to study treatment administration.
Part 2: received any biologics including investigational agents within 2.5 half-lives prior to Baseline.

What this trial measures

  • Number of Participants with Adverse Events (AEs)Up to Approximately Day 365

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.